One of the essential elements for developing safe and effective gene therapies is ensuring the quality of recombinant adeno-associated virus (rAAV) vectors used to deliver genetic material into specific tissues.

At NewBiologix, we use advanced analytical procedures to ensure the highest quality of encapsidated rAAV DNA. The NewBiologix Xcell^TM rAAV Analytics platform enables quantitative assessment of  the integrity of the rAAV genome and the presence of encapsidated contaminants, including residual plasmid DNA, host cell DNA and other unwanted DNA sequences. This is achieved through two powerful analytical approaches:

Multidimensional digital PCR (dPCR):

• Enables genome quantification and integrity assessment in a single reaction
• Differentiates between full and partial rAAV genomes
• Requires minimal sample preparation (compatible with crude supernatant)

Long-read Next-Generation Sequencing (NGS):

• Long-read sequencing technologies are used for evaluating integrity and quality of rAAV
• Provides high-resolution insights into rAAV sequence variants, structural changes, and unwanted encapsidated contaminants
• Supported by an in-house team of technical experts and custom-built bioinformatics pipelines